

DAFTAR PUSTAKA

- Akbari, Fresha; Kjellerup, Birthe. 2015. Elimination of Bloodstream Infections Associated with *Candida albicans* Biofilm in Intravascular Catheters. *Pathogens*, vol. 4 no. 3, page 457–469
- Andriole, T.V. 2000. *The Quinolone 3rd edition*. London: Academic Press
- Bush, N., Evans-Roberts, K., Maxwell, A. 2015. DNA Topoisomerases. *EcoSal Plus*, vol. 6, no. 2, p. 1-6
- CDC. *Healthcare-associated Infections. Diakses dari* <https://www.cdc.gov/hai/index.html>, pada tanggal 11 Februari 2019
- Champoux, J.J. 2001. DNA Topoisomerases: Structure, Function, And Mechanism. *Annual Review of Biochemistry*, vol. 70, page 369–413
- Chegene, Lorestani R., Akya, A., Elahi, A. 2018. The Mutations of Topoisomerase Genes and Their Effect on Resistance to Fluoroquinolones in Extended-Spectrum β -Lactamase-Producing *Escherichia coli*, *Jundishapur Journal of Natural Pharmaceutical Product*, vol. 13, no. 1, p. 1-15
- Donnenberg, Michael S. 2013. *Escherichia coli Pathotypes and Principles of Pathogenesis Second Edition*. USA: Elsevier, page 23-40
- Drlica K., Zhao, X.L. 1997. DNA Gyrase, Topoisomerase IV, and the 4-Quinolones. *Microbiology and Molecular Biology Reviews*, vol. 61, no. 3, p. 385-392
- Drlica, K., Malik, M., Kerns, J., Zhao, J., 2008. Minoreview: Quinolones Mediated Bacterial Death. *Antimicrobial Agent and Chemotherapy*, page 385-392
- El-Sokkary, M.M.A., Abdelmegeed, E.S. 2015. Antibacterial Resistance Pattern Among *Escherichia coli* Strain Isolated from Mansoura Hospital in Egypt with a Special Reference to Quinolones. *African Journal of Microbiology Research*, vol. 9, no. 9, page 662-670

- Fu, Y., Zhang, W., Wang, H., Zhao, S., Chen, Y., Meng, F., ... Zhang, F. 2013. Specific patterns of gyr A mutations determine the resistance difference to ciprofloxacin and levofloxacin in *Klebsiella pneumoniae* and *Escherichia coli*. *BMC Infectious Diseases*, vol. 13, no. 1, p. 1-13
- Garrett, R.H., Grisham, C.M. 2013. *Biochemistry 5th Edition*. United States: Mary Finch. page 949
- Gharib, Ahlam A., El-Aziz, Norhan K. Abd. 2013. Molecular Analysis of Quinolone Resistance-Determining Regions in Avian Pathogenic *Escherichia coli*. *International Journal of Advanced Research*, Volume 1, Issue 8, page 145-157
- Heeb, S., Fletcher, M. P., Chhabra, S. R., Diggle, S. P., Williams, P., Cámara, M. 2011. Quinolones: from antibiotics to autoinducers. *FEMS Microbiology Reviews*, vol. 35, no. 2, page 247–274
- Hooper, D. C., & Jacoby, G. A. 2015. Mechanisms of drug resistance: quinolone resistance. *Annals of the New York Academy of Sciences*, vol. 1354, no.1, page 12–31.
- Jang, Woo Hyuk, Yoo, Dong Hoon, Park, Seong Woon. 2011. Prevalence of and Risk Factor for Levofloxacin-Resistant *E. coli* Isolated from Outpatient with Urinary Tract Infection. *Korean Journal of Urology*, vol 52, no. 8 page 554-559
- Khan, Hasan Ahmed, Baig, Fatimah Kanwal, Mehboob, Rifat. 2015. Nosocomial infections and their control strategies. *Asian Pacific Journal of Tropical Biomedicine*, vol. 5, no.7, page 509-514
- Khan, Hasan Ahmed, Baig, Fatimah Kanwal, Mehboob, Rifat. 2017. Nosocomial infections: Epidemiology, prevention, control and surveillance. *Asian Pacific Journal of Tropical Biomedicine*, vol. 7, no.5, page 478–482
- Klevens, R. Monina; Edwards, Jonathan R.; Richards, Chesley L.; Horan, Teresa C.; Gaynes, Robert P; Pollock, Daniel A.; Cardo, Denise M. 2007.

- Estimating Healthcare-associated Infections and Deaths in U.S. Hospitals, 2002. *Public Health Reports*. Vol. 122 no. 2, page 160–166
- Lorestani, Roya Chegene; Akyam Alisha; Elahi, Azam. 2018. The Mutation of Topoisomerase Genes and Their Effect on Resistance to Fluoroquinolones in Extended-Spectrum β -Lactamase-Producing *Escherichia coli*. *Jundishapur J Nat Pharm Prod*. Vol. 13, no. 1, page 1-6
- Manning, Shannon D. 2010. *Escherichia coli Infection Second Editions*. New York: Chealse House Publsheer, page 16-84
- McGregor, J. C.; Allen, G. P.; Bearden, D. T. 2008. Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. *Therapeutics and clinical risk management*, vol. 4, page 843-853.
- Mitsher, L.A. 2005. Bacterial Topoisomerase Inhibitor: Quinolone and Pyridone Antibacterial Agent: In Chemical Review. *American Chemical Society*, page 587
- Nolan, T., Bustin, Stephen A. 2013. *PCR Technology Current Innovation 3th Edition*. New York: CRC Press Taylor & Francis Group, page 3-18
- Rawdon, E., Dorier, J., Račko, D., Millet, Kenneth C., Stasiak, A. 2016. How topoisomerase IV can efficiently unknot and decatenate negatively supercoiled DNA molecules without causing their torsional relaxation. *Nucleic Acids Research*, vol. 44, no. 10, page 4528–4538
- Redgrave, L. S., Sutton, S. B., Webber, M. A., & Piddock, L. J. V. 2014. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. *Trends in Microbiology*, 22(8), 438–445.
- Revelas A. 2012. Healthcare – Associated Infections: A Public Health Problem. *Nigerian Medical Journal*, vol. 53, issue 2, page 59-64.

- Ruiz , J. 2013. Mechanism of Resistance of Quinolone: Target Alteration, Decreased Accumulation and DNA Gyrase Protection. *Journal of Antimicrobiology Chemotherapy* vol. 51, page 1109-1117
- Ruzicka, M., Kulhanek, P., Radova, L., Cechova, A., Spackova, N., Fajkusova, L., Reblova, K., 2017. DNA mutation motifs in the genes associated with inherited diseases. *Plos One*; 12(8), 1-16
- Sai, H.Z., Lin, R.K., Hsieh, T.S. 2016. Drosophila mitochondrial topoisomerase III alpha affects the aging process via maintenance of mitochondrial function and genome integrity. *Journal of Biomedical Science*, vol. 23, no. 38
- Sharman, P.C., Jain, A., Jain, S. 2009. Fluoroquinolone Antibacterial: A Review on Chemistry, Microbiology and Therapeutic Prospect. Polish Pharmaceutical Society. *Acta Polonica Pharmaceutica-Drug Research*, vol. 66, no. 6, page 587-604
- Samadikuchaksaraei, Ali. 2016. *Polymerase Chain Reaction for Biomedical Applications*. London: InTechOpen, page 119-134
- Skold, Ola. 2011. *Antibiotic and Antibiotic Resistance*. Canada: A John Wiley & Sons, Inc, Publication, page 133-145
- Sobek, S., Boege, F.2014. DNA topoisomerases in mtDNA maintenance and ageing. *Experimental Gerontology*, vol. 56, page 135–141.
- Sorlozano, A., Gutierrez, J., Jimenez, A., de Dios Luna, J., & Martinez, J. L. 2007. Contribution of a New Mutation in parE to Quinolone Resistance in Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates. *Journal of Clinical Microbiology*, vol. 45, no. 8, page 2740–2742.
- Su, Lin-Hui; Ou, Jonathan T.; Leu, Hsieh-Shong; Chiang, Ping-Cherng; Chiu, Yueh-Pi; Chia, Ju-Hsin; Kuo, An-Jing; Chiu, Cheng-Hsun; Chu, Chishih. 2003. Extended Epidemic of Nosocomial Urinary Tract Infections Caused by *Serratia marcescens*. *Journal of Clinical Microbiology*. Vol. 41, no. 10, page 4726–4732

- Sutormin, D., Rubanova, N., Logacheva, M., Ghilarov, D., Severinov, K. 2018. Single-nucleotide-resolution mapping of DNA gyrase cleavage sites across the *Escherichia coli* genome. *Nucleic Acids Research*, vol. 1, no. 1, page 33-40
- Tenaillon O, Skurnik D, Picard B, Denamur E. 2010. The Population Genetics of Commensal *Escherichia coli*. *Nature Reviews. Microbiology*, vol. 8, no. 3, page 207–17
- Tortora, Gerard. 2010. *Microbiology: An Introduction*. San Francisco, CA: Benjamin Cummings. page. 85–87
- Turnidge, J.D., Ferraro, M.J., Jorgensen, J.H. 2003. *Susceptibility Test Methods: General Considerations*. In PR Murray, EJ Baron, JH Jorgensen, MA Tenover, RH Tenover. *Manual of Clinical Microbiology*. 8th Ed. Washington: American Society of Clinical Microbiology. p 1103
- Varughese, Lesley R., Rajpoot, M., Goyal, S., Mehra, R., Chhokar, V., Beniwah, V. 2018. Analytical profiling of mutations in quinolone resistance determining region of *gyrA* gene among UPEC. *PLoS ONE*, vol. 13, no. 1, page 1-9
- Vologodskii, A. 2011. Unlinking of supercoiled DNA catenanes by type IIA topoisomerases. *Biophysical Journal*, vol. 101, no. 6, page 1403–1411
- Wang Hui, Joann, L. Dzik-Fox, Chen, Minjun, Levy, Stuart B. 2001. Genetic Characterization of Highly Fluoroquinolone-Resistant Clinical *Escherichia coli* Strains from China: Role of *acrR* Mutations. *Antimicrobial Agents And Chemotherapy*, vol. 45, no. 5, page 1515-1521
- WHO. 2004. Prevention of hospital-acquired infections A practical guide 2nd edition. *World Health Organization Department of Communicable Disease, Surveillance and Response*
- Zayed, A. A.-F., Essam, T. M., Hashem, A.-G. M., & El-Tayeb, O. M. 2015. “Supermutators” found amongst highly levofloxacin-resistant *E. coli*

isolates: a rapid protocol for the detection of mutation sites. *Emerging
Microbes & Infections*, vol. 4, no. 1 page 1-11